Analysts Set Expectations for Fractyl Health FY2028 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Equities researchers at HC Wainwright increased their FY2028 earnings estimates for shares of Fractyl Health in a research report issued on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $0.03 per share for the year, up from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Fractyl Health’s FY2029 earnings at $0.38 EPS and FY2030 earnings at $0.95 EPS.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02.

Several other equities research analysts have also issued reports on the stock. Craig Hallum assumed coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings downgraded shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Fractyl Health has a consensus rating of “Moderate Buy” and a consensus price target of $5.12.

Fractyl Health Stock Performance

Shares of NASDAQ GUTS opened at $0.70 on Wednesday. The firm has a market capitalization of $111.34 million, a price-to-earnings ratio of -0.80 and a beta of 2.32. Fractyl Health has a one year low of $0.38 and a one year high of $2.44. The business has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $0.69. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41.

Institutional Investors Weigh In On Fractyl Health

Hedge funds have recently made changes to their positions in the company. Woodline Partners LP lifted its holdings in Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after purchasing an additional 165,786 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Fractyl Health during the second quarter worth about $129,000. General Catalyst Group Management LLC bought a new stake in Fractyl Health during the second quarter worth about $7,912,000. Jane Street Group LLC acquired a new stake in shares of Fractyl Health during the second quarter worth approximately $31,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Fractyl Health by 460.3% during the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after buying an additional 49,000 shares in the last quarter.

Insider Activity at Fractyl Health

In related news, Director Ian Sheffield bought 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the transaction, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William Bradley purchased 68,493 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the purchase, the director owned 84,622 shares in the company, valued at $61,774.06. This represents a 424.66% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 171,493 shares of company stock valued at $127,150 in the last 90 days. 8.52% of the stock is owned by corporate insiders.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.